Fresenius Medical Care (NYSE:FMS - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of $0.41 per share and revenue of $5.65 billion for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.
Fresenius Medical Care Stock Down 3.3 %
Shares of FMS stock traded down $0.80 during mid-day trading on Friday, hitting $23.46. The stock had a trading volume of 348,953 shares, compared to its average volume of 235,605. Fresenius Medical Care has a 12-month low of $17.93 and a 12-month high of $25.25. The firm has a market capitalization of $13.76 billion, a P/E ratio of 19.38, a price-to-earnings-growth ratio of 0.80 and a beta of 0.93. The firm's 50-day moving average is $23.47 and its two-hundred day moving average is $21.49. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.
Analyst Ratings Changes
A number of brokerages recently weighed in on FMS. Bank of America upgraded Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research note on Monday, December 2nd. Truist Financial upped their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. Berenberg Bank assumed coverage on Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a "buy" rating and a $25.60 price target for the company. Finally, StockNews.com upgraded Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th.
View Our Latest Research Report on Fresenius Medical Care
About Fresenius Medical Care
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Read More
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
